NASDAQ:EVFM Evofem Biosciences (EVFM) Stock Price, News & Analysis $0.01 +0.00 (+5.26%) As of 02:43 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Evofem Biosciences Stock (NASDAQ:EVFM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Evofem Biosciences alerts:Sign Up Key Stats Today's Range$0.0095▼$0.0150-Day Range$0.0089▼$0.0152-Week Range$0.0061▼$0.0150Volume166,124 shsAverage Volume413,854 shsMarket Capitalization$1.19 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California. Read More Evofem Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks25th Percentile Overall ScoreEVFM MarketRank™: Evofem Biosciences scored higher than 25% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Evofem Biosciences. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Evofem Biosciences is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evofem Biosciences is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of Evofem Biosciences has been sold short.Short Interest Ratio / Days to CoverEvofem Biosciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evofem Biosciences has recently decreased by 99.84%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEvofem Biosciences does not currently pay a dividend.Dividend GrowthEvofem Biosciences does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-0.90 Percentage of Shares Shorted0.00% of the float of Evofem Biosciences has been sold short.Short Interest Ratio / Days to CoverEvofem Biosciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evofem Biosciences has recently decreased by 99.84%, indicating that investor sentiment is improving significantly. News and Social Media1.1 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Evofem Biosciences this week, compared to 0 articles on an average week.Search Interest3 people have searched for EVFM on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Evofem Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Evofem Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.01% of the stock of Evofem Biosciences is held by insiders.Percentage Held by InstitutionsOnly 0.22% of the stock of Evofem Biosciences is held by institutions.Read more about Evofem Biosciences' insider trading history. Receive EVFM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evofem Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EVFM Stock News HeadlinesEvofem Biosciences Updates Merger Agreement with AditxtAugust 26 at 8:52 PM | msn.comIllinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed LawAugust 21, 2025 | prnewswire.comBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. August 27 at 2:00 AM | Crypto 101 Media (Ad)Evofem says FDA Orange Book lists patent for Solosec treatmentAugust 19, 2025 | msn.comFDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and TrichomoniasisAugust 19, 2025 | prnewswire.comEvofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business UpdateAugust 14, 2025 | prnewswire.comEvofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE ConferenceAugust 5, 2025 | prnewswire.comPhexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary MommyJuly 15, 2025 | finance.yahoo.comSee More Headlines EVFM Stock Analysis - Frequently Asked Questions How have EVFM shares performed this year? Evofem Biosciences' stock was trading at $0.0099 at the beginning of the year. Since then, EVFM shares have increased by 0.0% and is now trading at $0.0099. How were Evofem Biosciences' earnings last quarter? Evofem Biosciences, Inc. (NASDAQ:EVFM) announced its quarterly earnings data on Friday, June, 16th. The biotechnology company reported ($1.85) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($15.00) by $13.15. The biotechnology company had revenue of $5.81 million for the quarter. Evofem Biosciences had a negative net margin of 46.42% and a negative trailing twelve-month return on equity of 91.97%. When did Evofem Biosciences' stock split? Evofem Biosciences shares reverse split on Thursday, May 18th 2023.The 1-125 reverse split was announced on Thursday, May 18th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Evofem Biosciences? Shares of EVFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Evofem Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evofem Biosciences investors own include Tesla (TSLA), NIO (NIO), Plug Power (PLUG), Meta Platforms (META), Sorrento Therapeutics (SRNE), NVIDIA (NVDA) and Ford Motor (F). Company Calendar Last Earnings6/16/2023Today8/27/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EVFM CIK1618835 Webwww.evofem.com Phone(858) 550-1900Fax844-828-2010Employees120Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$52.98 million Net Margins-46.42% Pretax Margin-46.42% Return on Equity-91.97% Return on Assets-61.93% Debt Debt-to-Equity RatioN/A Current Ratio0.11 Quick Ratio0.09 Sales & Book Value Annual Sales$11.39 million Price / Sales0.10 Cash FlowN/A Price / Cash FlowN/A Book Value($2.64) per share Price / Book0.00Miscellaneous Outstanding Shares118,656,000Free Float113,118,000Market Cap$1.13 million OptionableNot Optionable Beta-0.99 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:EVFM) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evofem Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evofem Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access